BioInvent Gets New Patent Protections for BI-505 as Possible Multiple Myeloma Treatment
BioInvent International has received further patent protection in China,…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreBioInvent International has received further patent protection in China,…
Newly diagnosed multiple myeloma patients who are using statins have…
PharmaMar has submitted a Marketing Authorization Application (MAA) to the …
The Multiple Myeloma Research Foundation (MMRF) and the…
The association between excess body fat and increased risk…
Minimal residual disease, a measurement that shows a low…